Summary
McKesson Corporation's Form 10-Q filing for the period ending December 30, 2020, reveals a significant net loss attributable to McKesson Corporation of $6.226 billion, or $39.03 per diluted share. This substantial loss is largely driven by a substantial charge of $8.1 billion related to estimated opioid-related litigation liabilities. Despite this significant charge, the company's revenue for the quarter increased by 6% year-over-year to $62.6 billion, and for the nine-month period by 4% to $179.1 billion, primarily due to growth in the U.S. Pharmaceutical segment and increased demand for COVID-19 tests and PPE in the Medical-Surgical Solutions segment. The company also reported changes in its segment reporting structure and continues to navigate the impacts of the COVID-19 pandemic, including its role as a distributor for COVID-19 vaccines and related supplies. While revenue growth is present, the significant litigation charge heavily impacts profitability. Investors should monitor the ongoing resolution of the opioid litigation and its ultimate financial impact, as well as the company's performance across its evolving business segments.
Financial Highlights
53 data points| Revenue | $62.60B |
| Cost of Revenue | $59.45B |
| Gross Profit | $3.15B |
| SG&A Expenses | $2.29B |
| Operating Expenses | $10.51B |
| Operating Income | -$7.36B |
| Interest Expense | $55.00M |
| Net Income | -$6.23B |
| EPS (Basic) | $-39.03 |
| EPS (Diluted) | $-39.03 |
| Shares Outstanding (Basic) | 159.50M |
| Shares Outstanding (Diluted) | 159.50M |
Key Highlights
- 1Net loss attributable to McKesson Corporation for the quarter was $6.226 billion ($39.03 per diluted share), primarily due to an $8.1 billion charge for opioid-related litigation.
- 2Quarterly revenue increased 6% to $62.6 billion, with the U.S. Pharmaceutical segment being a key driver of growth.
- 3The Medical-Surgical Solutions segment saw significant revenue growth (43% in the quarter) driven by demand for COVID-19 tests and PPE.
- 4McKesson is actively involved in the distribution of COVID-19 vaccines and ancillary supplies, supporting government efforts.
- 5The company completed the contribution of its German pharmaceutical wholesale business to a joint venture with Walgreens Boots Alliance.
- 6Despite the net loss, the company returned $709 million to shareholders through stock repurchases and dividends in the nine-month period, and authorized an additional $2.0 billion for future share repurchases.
- 7Operating expenses significantly increased due to the large litigation charge, though underlying operating expenses (excluding litigation and other charges) showed some cost savings initiatives related to COVID-19.